Investor Presentaiton
Investor Presentation
First six months of 2018
The GLP-1 segment accounts for around 5% of the total
diabetes care market in Region Japan & Korea
Japan & Korea GLP-1 market
Slide 72
VictozaⓇ value market share in Japan & Korea
GLP-1 value
in DKK
VictozaⓇ
exenatide
billion
dulaglutide Share of total
other
diabetes care
market
GLP-1 value
VictozaⓇ
market share
exenatide
dulaglutide
other
1.6
3%
100%
1.4
CAGR value¹: 23.3%
80%
1.2
2%
1.0
60%
56%
0.8
40%
0.6
36%
1%
0.4
20%
0.2
0.0
0%
0%
May
2013
May
2018
May
2013
4%
3%
May
2018
1 CAGR for 5-year period
Source: IQVIA monthly MAT May, 2018 value figures (DKK)
changing
diabetes®
Source: IQVIA monthly MAT May, 2018 value figures (DKK), market share does not add
up to 100% due to rounding
novo nordiskView entire presentation